BACKGROUND: +/-3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug that causes cognitive deficits in humans. A rat model for learning and memory deficits has not been established, although some cognitive deficits have been reported. METHODS: Male Sprague-Dawley rats were treated with MDMA (15 mg/kg x 4 doses) or saline (SAL) (n = 20/treatment group) and tested in different learning paradigms: 1) path integration in the Cincinnati water maze (CWM), 2) spatial learning in the Morris water maze (MWM), and 3) novel object recognition (NOR). One week after drug administration, testing began in the CWM, then four phases of MWM, and finally NOR. Following behavioral testing, monoamine levels were assessed. RESULTS: +/-3,4-Methylenedioxymethamphetamine-treated rats committed more CWM errors than did SAL-treated rats. +/-3,4-Methylenedioxymethamphetamine-treated animals were further from the former platform position during each 30-second MWM probe trial but showed no differences during learning trials with the platform present. There were no group differences in NOR. +/-3,4-Methylenedioxymethamphetamine depleted serotonin in all brain regions and dopamine in the striatum. CONCLUSIONS: +/-3,4-Methylenedioxymethamphetamine produced MWM reference memory deficits even after complex learning in the CWM, where deficits in path integration learning occurred. Assessment of path integration may provide a sensitive index of MDMA-induced learning deficits.
BACKGROUND: +/-3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug that causes cognitive deficits in humans. A rat model for learning and memory deficits has not been established, although some cognitive deficits have been reported. METHODS: Male Sprague-Dawley rats were treated with MDMA (15 mg/kg x 4 doses) or saline (SAL) (n = 20/treatment group) and tested in different learning paradigms: 1) path integration in the Cincinnati water maze (CWM), 2) spatial learning in the Morris water maze (MWM), and 3) novel object recognition (NOR). One week after drug administration, testing began in the CWM, then four phases of MWM, and finally NOR. Following behavioral testing, monoamine levels were assessed. RESULTS: +/-3,4-Methylenedioxymethamphetamine-treated rats committed more CWM errors than did SAL-treated rats. +/-3,4-Methylenedioxymethamphetamine-treated animals were further from the former platform position during each 30-second MWM probe trial but showed no differences during learning trials with the platform present. There were no group differences in NOR. +/-3,4-Methylenedioxymethamphetamine depleted serotonin in all brain regions and dopamine in the striatum. CONCLUSIONS: +/-3,4-Methylenedioxymethamphetamine produced MWM reference memory deficits even after complex learning in the CWM, where deficits in path integration learning occurred. Assessment of path integration may provide a sensitive index of MDMA-induced learning deficits.
Authors: R J Verkes; H J Gijsman; M S Pieters; R C Schoemaker; S de Visser; M Kuijpers; E J Pennings; D de Bruin; G Van de Wijngaart; J M Van Gerven; A F Cohen Journal: Psychopharmacology (Berl) Date: 2001-01-01 Impact factor: 4.530
Authors: Martha A Cohen; Matthew R Skelton; Tori L Schaefer; Gary A Gudelsky; Charles V Vorhees; Michael T Williams Journal: Synapse Date: 2005-09-01 Impact factor: 2.562
Authors: M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí Journal: Psychopharmacology (Berl) Date: 2004-04-08 Impact factor: 4.530
Authors: A Richard Green; Veronica Sanchez; Esther O'Shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado Journal: Psychopharmacology (Berl) Date: 2004-01-15 Impact factor: 4.530
Authors: R Thomasius; K Petersen; R Buchert; B Andresen; P Zapletalova; L Wartberg; B Nebeling; A Schmoldt Journal: Psychopharmacology (Berl) Date: 2003-03-11 Impact factor: 4.530
Authors: Ann M Hemmerle; Jonathan W Dickerson; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams; Kim B Seroogy Journal: J Comp Neurol Date: 2012-08-01 Impact factor: 3.215
Authors: Ratchanee Rodsiri; Clare Spicer; A Richard Green; Charles A Marsden; Kevin C F Fone Journal: Psychopharmacology (Berl) Date: 2010-07-20 Impact factor: 4.530
Authors: Matthew R Skelton; Jessica A Able; Curtis E Grace; Nicole R Herring; Tori L Schaefer; Gary A Gudelsky; Charles V Vorhees; Michael T Williams Journal: Neuropharmacology Date: 2008-07-12 Impact factor: 5.250
Authors: Devon L Graham; Nicole R Herring; Tori L Schaefer; Katherine D Holland; Charles V Vorhees; Michael T Williams Journal: Open Neuropsychopharmacol J Date: 2012
Authors: Michael T Williams; Nicole R Herring; Tori L Schaefer; Matthew R Skelton; Nicholas G Campbell; Jack W Lipton; Anne E McCrea; Charles V Vorhees Journal: Neuropsychopharmacology Date: 2006-10-18 Impact factor: 7.853
Authors: Petra S van Nieuwenhuijzen; Leonora E Long; Glenn E Hunt; Jonathon C Arnold; Iain S McGregor Journal: Psychopharmacology (Berl) Date: 2010-08-21 Impact factor: 4.530
Authors: Charles V Vorhees; Elizabeth He; Matthew R Skelton; Devon L Graham; Tori L Schaefer; Curtis E Grace; Amanda A Braun; Robyn Amos-Kroohs; Michael T Williams Journal: Synapse Date: 2010-10-08 Impact factor: 2.562